Cargando…
In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy
BACKGROUND: Major Histocompatibility Complex (MHC) or Human Leukocyte Antigen (HLA) Class I molecules bind to peptide fragments of proteins degraded inside the cell and display them on the cell surface. We are interested in peptide-HLA complexes involving peptides that are derived from proteins spec...
Autores principales: | Dhanik, Ankur, R. Kirshner, Jessica, MacDonald, Douglas, Thurston, Gavin, C. Lin, Hsin, J. Murphy, Andrew, Zhang, Wen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955262/ https://www.ncbi.nlm.nih.gov/pubmed/27439771 http://dx.doi.org/10.1186/s12859-016-1150-2 |
Ejemplares similares
-
Dll4-Notch signaling as a therapeutic target in tumor angiogenesis
por: Kuhnert, Frank, et al.
Publicado: (2011) -
A framework for highly multiplexed dextramer mapping and prediction of T cell receptor sequences to antigen specificity
por: Zhang, Wen, et al.
Publicado: (2021) -
In Silico Discovery of Anticancer Peptides from Sanghuang
por: Liu, Minghao, et al.
Publicado: (2022) -
Personalized HLA typing leads to the discovery of novel HLA alleles and tumor‐specific HLA variants
por: Anzar, Irantzu, et al.
Publicado: (2022) -
Spontaneous tumor regression mediated by human T cells in a humanized immune system mouse model
por: Patel, A. K., et al.
Publicado: (2023)